Natural product-based pharmaceutical development company Bichedam Co., Ltd. announced on the 2nd that it has completed its Pre-A round of investment by attracting 1 billion won in investment from the Technology Guarantee Fund. Through this investment, Bichedam has secured a cumulative investment of 2 billion won, including seed investment in 2024.
Bichedam is developing a ROCK (Rho-associated protein kinase) inhibitor based on herbal ingredients as its main technology, and has a degenerative disease treatment using this as its main pipeline. Currently, the new drug candidate is preparing to enter domestic phase 1 clinical trials in cooperation with Chungbuk National University Hospital.
In addition, Bichedam is also preparing to launch a premium health functional food product. The company plans to introduce a herbal medicine-based product that can help relieve lower extremity muscle cramps that occur during sleep and improve blood circulation by August.
Moon Ho-bin, CEO of Bichedam, said, “This investment attraction is the result of a high evaluation of our natural product-based technology and marketability,” and added, “In addition to developing new drugs centered on degenerative diseases, we will gradually lay the foundation for technology transfer and a future initial public offering (IPO) by entering the global market for functional products.”
- See more related articles
You must be logged in to post a comment.